PITTCON 18 - High Throughput monitoring of tranexamic acid in plasma using microfluidic open interface with flow isolated desorption volume.

Congress

Summary *

Tranexamic acid (TXA) is a drug used for antifibrinolytic therapy in a range of applications including high risk cardiac surgery. Unfortunately, it has proved difficult to maintain plasma concentrations of this drug within its therapeutic range during treatment which can lead to post-operative seizures especially for patients suffering from renal insufficiency. It is therefore important to develop efficient methodologies to monitor this drug more closely over the course of administration to better make corrections to the dosing schedule and in effect, tailor the treatment. In this context, the use of new and simple technologies such the microfluidic open interface (MOI) through flow isolated desorption volume emerge as an interface for the direct coupling of biocompatible solid-phase microextraction to tandem mass spectrometry (Bio-SPME-MOI-MS/MS).In this work, a cross validation between Bio-SPME-MOI-MS/MS and Bio-SPME-LC-MS/MS is conducted. Patient sample preparation was done via Bio-SPME using a hydrophilic-lipophilic balance (HLB) type coating. It must be noted that for MOI-MS/MS 4 mm Bio-SPME fibers were enough to reach the required LOQ while for the LC-MS/MS method the configuration that provided the best result was the blade. This methodology reduced analysis time from 10 minutes by way of LC to just 20 seconds per sample while keeping the same sensitivity. Linearity, precision and, LOQ were assessed for the techniques with values of r2>0,99, 15% and 10 ppm, respectively. The Bland-Altman plot of data pairs (n = 63) of Bio-SPME-MOI-MS/MS and Bio-SPME-LC-MS/MS showed that a 92.1% of the data fits within the acceptable range (interval of confidence ± 1.96 SD). Furthermore, the Deming regression gave a slope of 0.984, which is very close to the identity. These results demonstrate the suitability of this technology not only for high-throughput determination of TXAfrom plasma but also for different clinical applications where the time is a crucial variable. Information provided by the agent in SIGEVA